The Creeping Pearl Index: Distinguishing Between Clinical Trial Efficacy and Actual-Use Effectiveness

The Creeping Pearl Index: Distinguishing Between Clinical Trial Efficacy and Actual-Use Effectiveness

The Creeping Pearl Index: Distinguishing Between Clinical Trial Efficacy and Actual-Use Effectiveness
RestartResume
    Reversible contraception is widely used by virtually all reproductive aged women at some point in their lives, yet many patients and clinicians are...

    Available credits: 0.25

    Time to complete: 15 minutes

    Released:

    Valid until:

    Take Post-Test

    If you’ve already completed the activity.

    • Overview

      Reversible contraception is widely used by virtually all reproductive aged women at some point in their lives, yet many patients and clinicians are unaware of how effective their chosen methods actually are and how efficacy is determined in both clinical trials and the real world. 

      This article will discuss various methods of reversible combined hormonal contraception (CHC), historical trends in contraceptive clinical trial design, the impact of obesity on efficacy, FDA guidance for trial conduct, perfect and actual use data, and shared decision-making around contraceptive choice.  Of particular note is the information surrounding “the Creeping Pearl Index.”

    • Disclosure of Conflicts of Interest

      In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

      Faculty:

      David Portman, MD
      Adjunct Instructor Obstetrics and Gynecology
      Ohio State University
      CEO and Chief Medical Officer
      Sermonix Pharmaceuticals
      Columbus, OH 

      Research Support: Agile Therapeutics
      Consulting Fees: Agile Therapeutics, Evofem Biosciences, Sebela Pharmaceuticals
      Salary/Stocks: Sermonix Pharmaceuticals

      Reviewers/Content Planners/Authors:

      • Sean T. Barrett has nothing to disclose.
      • Amanda Hilferty has nothing to disclose.
      • Elizabeth Lurwick has nothing to disclose.
      • Anita Nelson, MD, FACOG receives consulting fees from Agile Therapeutics, AMAG, American Regent, Bayer HealthCare, Merck, Sebela Pharmaceuticals, and TherapeuticsMD; serves in the commercial interest speakers bureaus for American Regent, Bayer HealthCare, Merck, and TherapeuticsMD; and does contracted research for Agile Therapeutics, Evofem, Merck, Mithra, and Sebela Pharmaceuticals.
      • Robert Schneider, MSW has nothing to disclose.
    • Learning Objectives

      After participating in this educational activity, participants should be better able to:

      • Explain the advantages and drawbacks of contraceptive patches and non-LARC methods.
      • Discuss the scientific data underlying the “creeping Pearl Index” demonstrated in contemporary clinical trials of contraception.
    • Target Audience

      This activity is designed to meet the educational needs of obstetricians/gynecologists, nurse practitioners, physician assistants, nurses, certified nurse midwives, and primary care physicians with a focus on women’s health.

    • Accreditation and Credit Designation Statements

      Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Provider(s)/Educational Partner(s)

      Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

    • Commercial Support

      This activity is supported by an independent educational grant from Agile Therapeutics. 

    • System Requirements

      Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

    Facebook Comments

    Register

    We’re glad to see you’re enjoying Omnia Education…
    but how about a more personalized experience?

    Register for free